On November 8, 2023, the FDA finalized a guidance called Compliance Policy for Cosmetic Product Facility Registration and Cosmetic Product Listing, granting an extension for some approaching deadlines set in the Modernization of Cosmetic Regulations Act of 2022 (MoCRA), under the provisions of 21 U.S.C. §§ 361-364j.
These deadlines, which are detailed in previous summary reports titled: Amendments to Section VI of the Federal Food, Drug and Cosmetics Act in the Omnibus Bill and Preparing for the December 2023 MoCRA, have now been given further consideration. This extension of time is a significant regulatory decision, having the potential to influence a wide multitude of professionals working within the expansive cosmetic industry.
The decision to postpone these deadlines yet again falls within the extents of permissible regulation alterations by the FDA in their efforts to adapt to ongoing situations and challenges. The FDA has shown its readiness to facilitate businesses navigating their way through the ever-changing landscape of cosmetic regulations. By granting these extensions, the FDA is helping to ensure businesses have adequate time to become complicit with new provisions and avoid any penalties stemming from unintentional misalignments with the new statutes.
This decision, while potentially beneficial in terms of compliance, calls for meticulous tracking of changes by legal professionals working in the cosmetic sector. It highlights the necessity for precision in keeping up with the fluidity of regulatory provisions and aligning the firm’s practices accordingly, ensuring ongoing legal compliance.
Having insights on these regulatory changes and understanding their implications forms an integral part of a legal professional’s role in advising their respective organizations. With the wide range of modifications brought forward by MoCRA and its extensions, legal teams will have to engage in comprehensive review and analysis to fully interpret its potential influence on their respective institutions.
For more comprehensive information, review the finalized FDA guidance document here.